Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Conduct Follow-Up Health Survey on COVID-19 Vaccinations
November 9, 2021
- MHLW Panel Tables Decision on Efient’s Preventive Use for ICD Recurrences; Lilly's Migraine Med, Jardiance's Heart Failure Indication OK'ed
November 9, 2021
- Chuikyo Split over 2% Adjustment Rate, Off-Year Re-Pricing; JPWA Says Wholesalers Are in Dire Straits
November 8, 2021
- Industry Pushes PMP Coverage for Additional Indications, Payers See This Need Too but Only for Certain Products: Chuikyo
November 8, 2021
- Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing
November 8, 2021
- JGA Sees New Generics as Financial Resources Necessary to Increase Production Capacity: Chuikyo Hearing
November 8, 2021
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Herceptin’s Salivary Cancer Use Sails through PAFSC; Label Expansions for I/O Drugs, Lorbrena in Line for Approval
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Booster Shots to Start with Pfizer Vaccine: MHLW
November 2, 2021
- G20 Ministers Vow to Boost Vaccine Supply to Developing Countries
November 2, 2021
- Noda, Tokashiki, More in LDP Healthcare Clique Lose Seats in Lower House Poll
November 1, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- Late-Phase Trials with Overseas Participation Pragmatic Approach for Japan-Made COVID-19 Vaccine Development: PMDA Director
October 29, 2021
- Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
- Japan to Compile Emergency Proposal for Economic Security in Early November
October 27, 2021
- Health Minister Vows Early Approval of Oral COVID-19 Drugs
October 27, 2021
- Industry Calls for Simplifying Regulatory Process for SaMD
October 26, 2021
- Lilly’s Migraine Drug Lasmiditan, Jardiance’s Heart Failure Use Up for PAFSC Review on Nov. 5
October 26, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…